Yuanping Shi

Yuanping Shi

Auto-generated profile, based on publicly available information

Yuanping Shi

Department of Comprehensive Laboratory, the Third Affiliated Hospital of Soochow University, Changzhou, 213003, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2012 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
DDDongmei Di
Dongmei Di
ZWZongchun Wang
Zongchun Wang
YLYang Liu
Yang Liu
GLGuanghua Luo
Guanghua Luo
YSYuanping Shi
Yuanping Shi
NXNing Xu
Ning Xu

4 November 2011 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
CZChunhua Zhu
Chunhua Zhu
DDDongmei Di
Dongmei Di
XZXiaoying Zhang
Xiaoying Zhang
GLGuanghua Luo
Guanghua Luo
ZWZongchun Wang
Zongchun Wang
NXNing Xu
Ning Xu
Background: Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a liver X receptor (LXR) agonist, TO901317. Materials and methods: Caco-2 cells were cultured in the presence of either TO901317, farnesoid X receptor (FXR) antagonist guggulsterone or TO901317 together with guggulsterone at different concentrations for 24 hrs. The mRNA levels of ATP-binding cassette transporter A1 (ABCA1), apoA1, apoM, liver receptor homologue-1 (LRH-1) and short heterodimer partner 1 (SHP1) were determined by real-time RT-PCR. Results: When Caco-2 cell cultured with TO901317 alone, the mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 were significantly increased with dose-dependent manners (p < 0.05), whereas when the cells cultured with guggulsterone alone, the mRNA levels of apoM, SHP1 and LRH-1 (p < 0.05) were strongly inhibited. Moreover, guggulsterone could abolish the TO901317 enhanced mRNA levels of apoA1 apoM, SHP1 and LRH-1. Conclusion: The present study demonstrated that LXR agonist TO901317 induced apoM expression in Caco-2 cells might be mediated via the LXR/FXR pathway.

31 March 2017 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
JWJiang Wei
Jiang Wei
YYYang Yu
Yang Yu
GLGuanghua Luo
Guanghua Luo
YFYue-Hua Feng
Yue-Hua Feng
YSYuan-Ping Shi
Yuan-Ping Shi
NXNing Xu
Ning Xu
We have previously demonstrated that estrogen could significantly enhance expression of apolipoprotein M (apoM), whereas the molecular basis of its mechanism is not fully elucidated yet. To further investigate the mechanism behind the estrogen induced up-regulation of apoM expression. Our results demonstrated either free 17β-estradiol (E2) or membrane-impermeable bovine serum albumin-conjugated E2 (E2-BSA) could modulate human apoM gene expression via the estrogen receptor alpha (ER-α) pathway in the HepG2 cells. Moreover, experiments with the luciferase activity analysis of truncated apoM promoters could demonstrate that a regulatory region (from-1580 to −1575 bp (−GGTCA-)) upstream of the transcriptional start site of apoM gene was essential for the basal transcriptional activity that regulated by the ER-α. With the applications of an electrophoresis mobility shift assay and a chromatin immunoprecipitation assay, we could successfully identify a specific ER-α binding element in the apoM promoter region. In summary, the present study indicates that 17β-estradiol induced up-regulation of apoM in HepG2 cells is through an ER-α-dependent pathway involving ER-α binding element in the promoter of the apoM gene.